Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
暂无分享,去创建一个
[1] Martin Fortin,et al. Canadian Task Force on Preventive Health Care , 2012 .
[2] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[3] Hans Garmo,et al. Radical prostatectomy or watchful waiting in early prostate cancer. , 2014, The New England journal of medicine.
[4] P. Fransson,et al. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer , 2009, Scandinavian journal of urology and nephrology.
[5] Kathleen N Lohr,et al. Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.
[6] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[7] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[8] A. Miller. New data on prostate-cancer mortality after PSA screening. , 2012, The New England journal of medicine.
[9] H. Dubben. Trials of prostate-cancer screening are not worthwhile. , 2009, The Lancet. Oncology.
[10] G. Haas,et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.
[11] C. Newschaffer,et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. , 2000, Journal of the National Cancer Institute.
[12] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[13] T. Wilt,et al. The prostate cancer intervention versus observation trial , 1994 .
[14] T. Tammela,et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.
[15] J. Kaprio,et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.
[16] Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study , 2008, BJU international.
[17] Timothy J Wilt,et al. Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.
[18] F. Hamdy,et al. Measuring the psychosocial impact of population‐based prostate‐specific antigen testing for prostate cancer in the UK , 2006, BJU international.
[19] F. Labrie,et al. Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial , 2004, The Prostate.
[20] L. Holmberg,et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. , 2011, The Lancet. Oncology.
[21] Peter C Albertsen,et al. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.
[22] T. Tammela,et al. Prostate cancer mortality in the Finnish randomized screening trial. , 2013, Journal of the National Cancer Institute.
[23] T. Wilt. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer. , 2012, Journal of the National Cancer Institute. Monographs.
[24] Peter H Gann,et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.
[25] L. Holmberg,et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.
[26] Dirk F Moore,et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.
[27] P. Corso,et al. National Institutes of Health State-of-the-Science Conference , 2012 .
[28] Lisa M. Schwartz,et al. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. , 2005, Journal of the National Cancer Institute.
[29] D. Bates,et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. , 2004, The American journal of medicine.
[30] H. Welch,et al. Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.
[31] Rascon. [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.
[32] A. Vickers,et al. Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Gohagan,et al. Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening , 2009, The Annals of Family Medicine.
[34] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[35] T. Stukel,et al. Changing patterns in competing causes of death in men with prostate cancer: a population based study. , 2004, The Journal of urology.
[36] S. Lipsitz,et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. , 2009, JAMA.
[37] Dirk F Moore,et al. Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.
[38] M. Roobol,et al. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. , 2007, Journal of the National Cancer Institute.
[39] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[40] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[41] U. Norming,et al. 15-year followup of a population based prostate cancer screening study. , 2009, The Journal of urology.
[42] D. Bates,et al. The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes , 2006, Journal of General Internal Medicine.
[43] Matthew R Cooperberg,et al. Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] T. Wilt,et al. Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer , 2008, Annals of Internal Medicine.
[45] F. Hamdy,et al. Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer , 2009, BJU international.
[46] T. Gomes,et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. , 2012 .
[47] J. Kovář,et al. Calcium and magnesium infusions for prevention of oxaliplatin-induced peripheral neuropathy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[49] J. Hugosson,et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. , 2007, European urology.
[50] A. D'Amico,et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Therese Miller,et al. Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.
[52] Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.
[53] Anssi Auvinen,et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.
[54] T. Tammela,et al. False-positive screening results in the Finnish prostate cancer screening trial , 2010, British Journal of Cancer.
[55] S. Freedland,et al. Five-year downstream outcomes following prostate-specific antigen screening in older men. , 2013, JAMA internal medicine.
[56] Mohammad Hassan Murad,et al. Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[57] Andrew J Vickers,et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. , 2011, Journal of the National Cancer Institute.
[58] A. Chokkalingam,et al. Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.
[59] P. Keegan,et al. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. , 2011, The New England journal of medicine.
[60] M. Stampfer,et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.
[61] Jim C Hu,et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.
[62] T. Tammela,et al. False-positive screening results in the European randomized study of screening for prostate cancer. , 2011, European journal of cancer.
[63] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[64] Christina Bougatsos,et al. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.
[65] F. Hamdy,et al. The ProtecT trial: evaluating the effectiveness of treatments for clinically localised prostate cancer , 2009 .
[66] T. Wilt,et al. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer , 2008 .
[67] B. G. Blijenberg,et al. Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.
[68] Christina Bougatsos,et al. Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation , 2011 .
[69] Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy , 2010 .
[70] H Ballentine Carter,et al. Complications after prostate biopsy: data from SEER-Medicare. , 2011, The Journal of urology.
[71] A. D'Amico,et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.
[72] H. Koenig,et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer , 2011 .
[73] K. Sherin,et al. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. , 2008, American journal of preventive medicine.
[74] D. Corle,et al. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. , 1995, Scandinavian journal of urology and nephrology. Supplementum.
[75] E. Steyerberg,et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC , 2010, International journal of cancer.
[76] J. Gohagan,et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.
[77] Timothy J Wilt,et al. Prevention and early detection of prostate cancer. , 2014, The Lancet. Oncology.
[78] Ian M Thompson,et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.
[79] Gerhard Jentzsch,et al. Working group on , 1991 .
[80] M. Tonelli,et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test , 2014, Canadian Medical Association Journal.
[81] O. Löfman,et al. Randomised prostate cancer screening trial: 20 year follow-up , 2011, BMJ : British Medical Journal.
[82] P. Walsh,et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. , 2003, Journal of Urology.
[83] Chris Metcalfe,et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.
[84] P. Corso,et al. National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer , 2012, Annals of Internal Medicine.
[85] Erik Holmberg,et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.
[86] P. Prorok,et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial , 2010, Clinical trials.
[87] L. Schwartz,et al. The benefits and harms of mammography screening: understanding the trade-offs. , 2010, JAMA.
[88] T. Wilt,et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. , 2009, Contemporary clinical trials.
[89] B. Levin,et al. American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.
[90] Douglas K Owens,et al. Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians , 2013, Annals of Internal Medicine.
[91] T. Wilt,et al. Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.
[92] D. Katz,et al. Health perceptions in patients who undergo screening and workup for prostate cancer. , 2007, Urology.